Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer

BACKGROUND: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in the phase 3 ALSYMPCA study. ALSYMPCA was conducted when fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Higano, Celestia S., George, Daniel J., Shore, Neal D., Sartor, Oliver, Miller, Kurt, Conti, Peter S., Sternberg, Cora N., Saad, Fred, Sade, Juan Pablo, Bellmunt, Joaquim, Smith, Matthew R., Chandrawansa, Kumari, Sandström, Per, Verholen, Frank, Tombal, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209672/
https://www.ncbi.nlm.nih.gov/pubmed/37251627
http://dx.doi.org/10.1016/j.eclinm.2023.101993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209672/
https://www.ncbi.nlm.nih.gov/pubmed/37251627
http://dx.doi.org/10.1016/j.eclinm.2023.101993

Ejemplares similares